SLC5A2 and diabetic kidney disease: For patients with DKD and eGFR >20 mL/min/1.73 m2,treatment with an SGLT2 inhibitor can be initiated as part of thestandard of care along with ACEi/ARB use, BP control, and A1Ccontrol.